Eisai Collaborates with BMS for the Co-Development and Co-Commercialization of MORAb-202
Shots:
- Eisai to receive $650M including $200M as R&D expenses and is eligible to receive ~2.45B as milestones along with royalties on sales outside of collaboration territories. The companies will jointly develop & commercialize MORAb-202 and share profits & costs in collaboration territories
- BMS will lead the development & commercialization outside the collaboration territories while Eisai will remain responsible to manufacture & supply MORAb-202 globally
- Eisai is currently evaluating it in 2 studies i.e P-I study in Japan & P-I/II study in the US for FRα-positive solid tumors while companies plan to move into a registrational stage of development in 2022
Ref: Business Wire | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com